1393813-40-5

Usage

Uses

Used in Pharmaceutical Industry:
CarbaMic acid, N-[(propylaMino)sulfonyl]-, 1,1-diMethylethyl ester is used as a reagent in the synthesis of pharmaceutical compounds. Its unique functional groups, such as propylaMino and sulfonyl, may contribute to the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
CarbaMic acid, N-[(propylaMino)sulfonyl]-, 1,1-diMethylethyl ester may also have potential applications in the agrochemical industry, where it can be used as a precursor in the synthesis of agrochemicals with specific pesticidal or herbicidal properties. The presence of the sulfonyl group may contribute to the compound's activity against pests or weeds.
Used in Organic Chemistry Research:
As a derivative of carbaMic acid, CarbaMic acid, N-[(propylaMino)sulfonyl]-, 1,1-diMethylethyl ester is used in organic chemistry research to explore its reactivity and potential applications in various chemical reactions. Its stability and non-reactivity make it a suitable candidate for use as a precursor in synthesis reactions, allowing researchers to investigate its properties and potential uses in more detail.

Upstream product

• 107-10-8 propylamine 
• 147000-89-3 N-tert-butyloxycarbonylsulfamoyl chloride 
• 1189-71-5 isocyanate de chlorosulfonyle 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 147962-41-2 N-propylaminosulfonamide 

Relevant academic research and scientific papers

Simple, rapid, and clean condensation of sulfonamide and maleic anhydride derivatives: Synthesis of novel 1H- Pyrrole-2,5-diones under heterogeneous conditions

H6P2W18O62is used as an efficient catalyst for the synthesis of novel N-substituted sulfonyl maleimides (1H-Pyrrole-2,5-diones) via the condensation of sulfonamide and maleic anhydride derivatives. The Dawson heteropolyacid was used with a catalytic amount of 2?mmol% in acetonitrile at reflux. The reuse of H6P2W18O62as heterogeneous catalyst several times without decrease in their activity, short reaction times, easy isolation of desired products with good to excellent yields shows the advantages of this novel methodology.

PYRIMIDINE SULFAMIDE DERIVATIVE AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF

Disclosed are a series of pyrimidine sulfamide compounds and applications thereof in preparing a drug for a disease related to an ETA receptor antagonist. In particular, disclosed is a derived compound represented by formula (I) or a tautomer or pharmaceutically acceptable composition thereof.

Synthesis and antitumor evaluation of novel sulfonylcycloureas derived from nitrogen mustard

A new series of sulfonylcycloureas derivatives have been synthesized and evaluated in vitro for their antitumor activity against four cancer cell lines (A431, Jurkat, U266, and K562). These compounds were prepared by the condensation of several sulfonamides (2am) with ethyl bis(2-chloroethyl)carbamate (1a). The relative cytotoxicity of these new derivatives in comparison to chlorambucil is reported.

Synthesis of new substituted N-sulfonyl pyrrolidine-2,5-dione using dawson-type heteropolyacid as catalyst

The synthesis of new series of pyrrolidine-2,5-diones having sulfonamide moieties is described. These compounds are synthesized in good yield in three steps (carbamoylation-sulfamoylation, deprotection and condensation) using a catalytic amount of H6P2W18O62 in acetonitrile under refluxing conditions.

An efficient method for the synthesis of novel n-acylsulfonamides using tin (IV) chloride as catalysts

A series of novel N-acylsulfonamides derivatives were synthesized via direct condensation of parent sulfonamide with ethyl lactate as an acylating agent in the presence of tin (IV) chloride (SnCl4) as a Lewis acid catalyst. The sulfonamides were prepared, starting from chlorosulfonyl isocyanate (CSI), in three steps (carbamoylation, sulfamoylation, and deprotection) with excellent yields. Copyright

The discovery of N -[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy] ethoxy]-4-pyrimidinyl]- N ′-propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist

Starting from the structure of bosentan (1), we embarked on a medicinal chemistry program aiming at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy. This led to the discovery of a novel series of alkyl sulfamide substituted pyrimidines. Among these, compound 17 (macitentan, ACT-064992) emerged as particularly interesting as it is a potent inhibitor of ETA with significant affinity for the ET B receptor and shows excellent pharmacokinetic properties and high in vivo efficacy in hypertensive Dahl salt-sensitive rats. Compound 17 successfully completed a long-term phase III clinical trial for pulmonary arterial hypertension.